Literature DB >> 6721735

Cerebellar norepinephrine in patients with Parkinson's disease and control subjects.

S J Kish, K S Shannak, A H Rajput, J J Gilbert, O Hornykiewicz.   

Abstract

Norepinephrine was measured in postmortem cerebellar cortex of 22 non-neurological control subjects and nine patients with Parkinson's disease, using the high-performance liquid chromatography method with amperometric detection. In all control subjects, substantial amounts of norepinephrine was found in cerebellar cortex. There was a moderate negative correlation between age of control subjects and cerebellar norepinephrine concentration. In the patients with Parkinson's disease, the cerebellar cortical norepinephrine levels were significantly below normal. This is in accord with previously reported reduced norepinephrine levels in locus ceruleus and other regions of the parkinsonian brain. Although the main symptoms of Parkinson's disease are primarily caused by disturbed basal ganglia (dopamine) function, cerebellar dysfunction related to norepinephrine may contribute to some abnormalities of motor performance in this disorder.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6721735     DOI: 10.1001/archneur.1984.04210080020007

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  16 in total

1.  Neuron specific alpha-adrenergic receptor expression in human cerebellum: implications for emerging cerebellar roles in neurologic disease.

Authors:  U B Schambra; G B Mackensen; M Stafford-Smith; D E Haines; D A Schwinn
Journal:  Neuroscience       Date:  2005       Impact factor: 3.590

Review 2.  Behavioral and neurophysiological correlates of striatal dopamine depletion: a rodent model of Parkinson's disease.

Authors:  Emily K Plowman; Jeffrey A Kleim
Journal:  J Commun Disord       Date:  2011-04-30       Impact factor: 2.288

Review 3.  Dysautonomia in Parkinson disease.

Authors:  David S Goldstein
Journal:  Compr Physiol       Date:  2014-04       Impact factor: 9.090

4.  Cerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson's disease and other synucleinopathies.

Authors:  David S Goldstein; Courtney Holmes; Yehonatan Sharabi
Journal:  Brain       Date:  2012-03-26       Impact factor: 13.501

5.  Structural covariance networks of striatum subdivision in patients with Parkinson's disease.

Authors:  Kun-Hsien Chou; Wei-Che Lin; Pei-Lin Lee; Nai-Wen Tsai; Yung-Cheng Huang; Hsiu-Ling Chen; Kuei-Yueh Cheng; Pei-Chin Chen; Hung-Chen Wang; Tsu-Kung Lin; Shau-Hsuan Li; Wei-Ming Lin; Cheng-Hsien Lu; Ching-Po Lin
Journal:  Hum Brain Mapp       Date:  2014-12-31       Impact factor: 5.038

6.  Lesioning noradrenergic neurons of the locus coeruleus in C57Bl/6 mice with unilateral 6-hydroxydopamine injection, to assess molecular, electrophysiological and biochemical changes in noradrenergic signaling.

Authors:  P Szot; L Knight; A Franklin; C Sikkema; S Foster; C W Wilkinson; S S White; M A Raskind
Journal:  Neuroscience       Date:  2012-04-25       Impact factor: 3.590

7.  Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: relevance to the pathogenesis of Parkinson's disease.

Authors:  David S Goldstein; Patti Sullivan; Adele Cooney; Yunden Jinsmaa; Rachel Sullivan; Daniel J Gross; Courtney Holmes; Irwin J Kopin; Yehonatan Sharabi
Journal:  J Neurochem       Date:  2012-10-25       Impact factor: 5.372

8.  Hypertension increases cerebral 6-18F-fluorodopa-derived radioactivity.

Authors:  David S Goldstein; Courtney Holmes; Latoya Sewell; Irwin J Kopin
Journal:  J Nucl Med       Date:  2009-08-18       Impact factor: 10.057

9.  Neuron-astrocyte interactions in neurodegenerative diseases: Role of neuroinflammation.

Authors:  Kakulavarapu V Rama Rao; Tammy Kielian
Journal:  Clin Exp Neuroimmunol       Date:  2015-08-03

10.  Firing activity of locus coeruleus noradrenergic neurons increases in a rodent model of Parkinsonism.

Authors:  Tao Wang; Qiao-Jun Zhang; Jian Liu; Zhong-Heng Wu; Shuang Wang
Journal:  Neurosci Bull       Date:  2009-02       Impact factor: 5.203

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.